145 related articles for article (PubMed ID: 9781067)
1. [Is interleukin 2 useful in oncology?].
Négrier S
Rev Prat; 1998 Feb; 48(3):237-9. PubMed ID: 9781067
[No Abstract] [Full Text] [Related]
2. New therapies for malignant melanoma.
Hancock B
Practitioner; 1989 Oct; 233(1477):1385-6, 1388. PubMed ID: 2482487
[TBL] [Abstract][Full Text] [Related]
3. Relapse after successful treatment with immunotherapy: lessons for the future.
Fisher RI
Cancer J Sci Am; 1998; 4(2):78-9. PubMed ID: 9532407
[No Abstract] [Full Text] [Related]
4. Renal metastasis of malignant melanoma with unknown primary.
Shimko MS; Jacobs SC; Phelan MW
Urology; 2007 Feb; 69(2):384.e9-10. PubMed ID: 17320691
[TBL] [Abstract][Full Text] [Related]
5. IL-2 therapy proves durable in renal cell melanoma patients.
Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
[No Abstract] [Full Text] [Related]
6. [Cytokines and cancer: update in 1998].
Négrier S
Bull Cancer; 1999 Jan; 86(1):37-9. PubMed ID: 10029702
[No Abstract] [Full Text] [Related]
7. Treatment of melanoma in-transit metastases confined to the limb.
Eggermont AM
Cancer Surv; 1996; 26():335-49. PubMed ID: 8783582
[No Abstract] [Full Text] [Related]
8. [Immunotherapy of malignant diseases].
Dorval T; Michon J; Tartour E; Fridman WH
Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
[TBL] [Abstract][Full Text] [Related]
9. Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma.
Bernhardt MB; Hicks MJ; Pappo AS
Pediatr Blood Cancer; 2009 Dec; 53(7):1346-8. PubMed ID: 19731326
[TBL] [Abstract][Full Text] [Related]
10. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
11. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
12. Interferon adjuvant therapy of melanoma.
Nathanson L
Cancer; 1996 Sep; 78(5):944-7. PubMed ID: 8780530
[No Abstract] [Full Text] [Related]
13. [Abscopal effect in the treatment of malignant melanoma].
Thallinger C; Prager G; Ringl H; Zielinski C
Hautarzt; 2015 Jul; 66(7):545-8. PubMed ID: 25576145
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous head and neck melanoma: the old and the new.
Rigual NR; Popat SR; Jayaprakash V; Jaggernauth W; Wong M
Expert Rev Anticancer Ther; 2008 Mar; 8(3):403-12. PubMed ID: 18366288
[TBL] [Abstract][Full Text] [Related]
15. Determinants of outcome in melanoma patients with cerebral metastases.
Fife KM; Colman MH; Stevens GN; Firth IC; Moon D; Shannon KF; Harman R; Petersen-Schaefer K; Zacest AC; Besser M; Milton GW; McCarthy WH; Thompson JF
J Clin Oncol; 2004 Apr; 22(7):1293-300. PubMed ID: 15051777
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma.
Smyth JF
Cancer Chemother Biol Response Modif; 1991; 12():591-602. PubMed ID: 1718379
[No Abstract] [Full Text] [Related]
17. [Prognostic factors and improving treatment of cutaneous melanoma].
Vihinen P; Kähäri VM; Pyrhönen S
Duodecim; 2004; 120(12):1445-56. PubMed ID: 15293705
[No Abstract] [Full Text] [Related]
18. Induction of tolerance in autoimmune diseases rather than cure of cancer by interleukin-2 therapy.
Dejaco C; Duftner C; Schirmer M
J Clin Oncol; 2006 Jul; 24(20):e34; author reply e35-6. PubMed ID: 16829643
[No Abstract] [Full Text] [Related]
19. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
20. Biological therapy for metastatic renal cell cancer.
Lancet; 1991 Mar; 337(8740):522-3. PubMed ID: 1705643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
